Literature DB >> 34475524

Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.

Thomas Pincez1, Raoul Santiago1, Michel Duval2,3, Sonia Cellot1,4, Henrique Bittencourt1,4, Isabelle Louis1, Mélanie Bilodeau1, Alexandre Rouette5, Loubna Jouan6, Josette-Renée Landry4, Françoise Couture5, Johanne Richer1, Pierre Teira1,4.   

Abstract

Posttransplant leukemia detection before overt relapse is key to the success of immunotherapeutic interventions, as they are more efficient when leukemia burden is low. However, optimal schedule and monitoring methods are not well defined. We report the intensive bone marrow monitoring of minimal residual disease (MRD) using flow cytometry (FC) and nested reverse transcription polymerase chain reaction (RT-PCR) whenever a fusion transcript allowed it and chimerism by PCR at 11 timepoints in the first 2 years after transplant. Seventy-one transplants were performed in 59 consecutive children, for acute myeloid (n = 38), lymphoid (n = 31), or mixed-phenotype (n = 2) leukemia. MRD was monitored in 62 cases using FC (n = 58) and/or RT-PCR (n = 35). Sixty-seven percent of leukemia recurrences were detected before overt relapse, with a detection rate of 89% by RT-PCR and 40% by FC alone. Increased mixed chimerism was never the first evidence of recurrence. Two patients monitored by RT-PCR relapsed without previous MRD detection, one after missed scheduled evaluation and the other 4.7 years post transplant. Among the 22 cases with MRD detection without overt relapse, 19 received therapeutic interventions. Eight (42%) never relapsed. In conclusion, intensive marrow monitoring by RT-PCR effectively allows for early detection of posttransplant leukemia recurrence.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34475524     DOI: 10.1038/s41409-021-01408-5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  50 in total

Review 1.  A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia.

Authors:  Denise Niewerth; Ursula Creutzig; Marc B Bierings; Gertjan J L Kaspers
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  Acute Lymphoblastic Leukemia in Children.

Authors:  Stephen P Hunger; Charles G Mullighan
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

3.  Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.

Authors:  Peter J Shaw; Fangyu Kan; Kwang Woo Ahn; Stephen R Spellman; Mahmoud Aljurf; Mouhab Ayas; Michael Burke; Mitchell S Cairo; Allen R Chen; Stella M Davies; Haydar Frangoul; James Gajewski; Robert Peter Gale; Kamar Godder; Gregory A Hale; Martin B A Heemskerk; John Horan; Naynesh Kamani; Kimberly A Kasow; Ka Wah Chan; Stephanie J Lee; Wing H Leung; Victor A Lewis; David Miklos; Machteld Oudshoorn; Effie W Petersdorf; Olle Ringdén; Jean Sanders; Kirk R Schultz; Adriana Seber; Michelle Setterholm; Donna A Wall; Lolie Yu; Michael A Pulsipher
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

4.  Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.

Authors:  David R Freyer; Meenakshi Devidas; Mei La; William L Carroll; Paul S Gaynon; Stephen P Hunger; Nita L Seibel
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

Review 5.  Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.

Authors:  C Uderzo; G Dini; F Locatelli; R Miniero; P Tamaro
Journal:  Haematologica       Date:  2000-11       Impact factor: 9.941

6.  How I treat relapsed childhood acute lymphoblastic leukemia.

Authors:  Franco Locatelli; Martin Schrappe; Maria Ester Bernardo; Sergio Rutella
Journal:  Blood       Date:  2012-08-15       Impact factor: 22.113

7.  Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

Authors:  Wing Leung; Ching-Hon Pui; Elaine Coustan-Smith; Jie Yang; Deqing Pei; Kwan Gan; Ashok Srinivasan; Christine Hartford; Brandon M Triplett; Mari Dallas; Asha Pillai; David Shook; Jeffrey E Rubnitz; John T Sandlund; Sima Jeha; Hiroto Inaba; Raul C Ribeiro; Rupert Handgretinger; Joseph H Laver; Dario Campana
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

8.  Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Authors:  Menachem Bitan; Wensheng He; Mei-Jie Zhang; Hisham Abdel-Azim; Mouhab Fakhreddine Ayas; Bella Bielorai; Paul A Carpenter; Mitchell S Cairo; Miguel Angel Diaz; John T Horan; Sonata Jodele; Carrie L Kitko; Kirk R Schultz; Morris Kletzel; Kimberly A Kasow; Leslie E Lehmann; Parinda A Mehta; Nirali Shah; Michael A Pulsipher; Tim Prestidge; Adriana Seber; Shalini Shenoy; Ann E Woolfrey; Lolie C Yu; Stella M Davies
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

Review 9.  How I treat pediatric acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113

10.  Outcomes after induction failure in childhood acute lymphoblastic leukemia.

Authors:  Martin Schrappe; Stephen P Hunger; Ching-Hon Pui; Vaskar Saha; Paul S Gaynon; André Baruchel; Valentino Conter; Jacques Otten; Akira Ohara; Anne Birgitta Versluys; Gabriele Escherich; Mats Heyman; Lewis B Silverman; Keizo Horibe; Georg Mann; Bruce M Camitta; Jochen Harbott; Hansjörg Riehm; Sue Richards; Meenakshi Devidas; Martin Zimmermann
Journal:  N Engl J Med       Date:  2012-04-12       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.